Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Sep 16;16(9):e0257277.
doi: 10.1371/journal.pone.0257277. eCollection 2021.

Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria

Affiliations
Randomized Controlled Trial

Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria

Angela E Oyo-Ita et al. PLoS One. .

Abstract

Vaccination is a cost-effective public health intervention, yet evidence abounds that vaccination uptake is still poor in many low- and middle-income countries. Traditional and Religious Leaders play a substantial role in improving the uptake of health services such as immunization. However, there is paucity of evidence on the cost-effectiveness of using such strategies. This study aimed to assess the cost-effectiveness of using a multi-faceted intervention that included traditional and religious leaders for community engagement to improve uptake of routine immunisation services in communities in Cross River State, Southern Nigeria. The target population for the intervention was traditional and religious leaders in randomly selected communities in Cross River State. The impact of the intervention on the uptake of routine vaccination among children 0 to 23 months was assessed using a cluster randomized trials. Outcome assessments were performed at the end of the project (36 months).The cost of the intervention was obtained from the accounting records for expenditures incurred in the course of implementing the intervention. Costs were assessed from the health provider perspective. The cost-effectiveness analysis showed that the incremental cost of the initial implementation of the intervention was US$19,357and that the incremental effect was 323 measles cases averted, resulting in an incremental cost-effectiveness ratio (ICER) of US$60/measles case averted. However, for subsequent scale-up of the interventions to new areas not requiring a repeat expenditure of some of the initial capital expenditure the ICER was estimated to be US$34 per measles case averted. Involving the traditional and religious leaders in vaccination is a cost-effective strategy for improving the uptake of childhood routine vaccinations.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Ozawa S., et al.., Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011–20. Health Affairs, 2016. 35(2): p. 199–207. doi: 10.1377/hlthaff.2015.1086 - DOI - PubMed
    1. Ozawa S., et al.., Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: A systematic review. Vaccine, 2012. 31(1): p. 96–108. doi: 10.1016/j.vaccine.2012.10.103 - DOI - PubMed
    1. Bosch-Capblanch X., Banerjee K., and Burton A., Unvaccinated children in years of increasing coverage: how many and who are they? Evidence from 96 low- and middle-income countries. 2012. 17(6): p. 697–710. doi: 10.1111/j.1365-3156.2012.02989.x - DOI - PubMed
    1. National Population Commission (NPC)[Nigeria] and ICF, Nigeria Demographic and Health Survey 2018. 2019, NPC and ICF: Abuja, Nigeria and Rockville, Maryland, USA.
    1. Rainey J.J., et al.., Reasons related to non-vaccination and under-vaccination of children in low and middle income countries: findings from a systematic review of the published literature, 1999–2009. Vaccine, 2011. 29(46): p. 8215–21. doi: 10.1016/j.vaccine.2011.08.096 - DOI - PubMed

Publication types

MeSH terms

Substances